NASDAQ
SELLAS Life Sciences Group, Inc. (SLS)
♥ 521 Thanks from members
SELLAS Life Sciences (SLS) is experiencing heightened market interest and institutional accumulation, fueled by anticipated Phase 3 REGAL trial data for galinpepimut-S (GPS) in acute myeloid leukemia, broader cancer vaccine momentum, and pipeline expansion despite ongoing net losses.